Locations:
Search
Cleveland Clinic researchers have developed a first-in-class drug that shows remarkable promise in treating Alzheimer's disease and cognitive disorders by targeting a specific brain receptor in a novel way.
The groundbreaking research, led by principal investigator, Dianne Perez, PhD, focuses on the α1A-Adrenergic Receptors (ARs). These proteins are well known to play crucial roles in blood pressure regulation, but also mediate neuroprotection and cognitive function.
"When we put the drug into an animal model of Alzheimer's disease, we saw essentially a complete reversal of the disease," explains Dr. Perez. "It reduced the beta-amyloid proteins back to almost normal levels, and there was no blood pressure effect."
What makes this approach revolutionary is the drug's ability to modulate the ARs without affecting blood pressure—a challenge that previously caused pharmaceutical companies to abandon similar research directions.
Shaun Stauffer, PhD, Director of Cleveland Clinic’s Center for Therapeutics Discovery (C3TD), collaborates with Dr. Perez to advance the treatment.
"These adrenergic receptors have never been targeted in this way before," notes Dr. Stauffer. "This is a first-in-class approach."
Unlike existing Alzheimer's treatments that primarily slow disease progression, this drug demonstrates the potential for both prevention and reversal. It achieves this by not only protecting surviving neurons but also promoting neurogenesis—the production of new neurons.
The research holds special significance for Dr. Perez, whose mother-in-law passed away from Alzheimer's disease, and whose husband is showing early signs of the condition.
With support from the Alzheimer's Drug Discovery Foundation, the team conducted safety studies required before human clinical trials can begin. The team hopes to meet U.S. Food and Drug Administration (FDA) standards for an Investigational New Drug (IND) application this year.
As the project progresses toward human trials, this Cleveland Clinic innovation represents a promising new direction in neurodegenerative disease treatment—one that could transform lives by potentially reversing a condition that affects millions worldwide.
For more information about Cleveland Clinic Innovations' therapeutics and diagnostics technologies, visit here.
